Moodle at CCNM

The purpose of this presentation is to allow the attendee a chance to “catch up” after a full day of genomic presentations and get an introduction to the day’s material. Dr. Anderson presents several case studies on patients he has managed. A “1-2-3” approach will be presented which outlines how practitioners can “troubleshoot” the treatment issues that happen when either the patient “self-treats” or has an unusual reaction to a nutrigenomic therapy.  Pharmaceuticals discussed in case presentations will include Deplin, Metanx, Buproprion, and Diphenhydramine.

How do the three phases of detoxification work? How do pharmaceuticals affect them? A common area of misunderstood reactivity is sulfite oxidation, which often is mistaken for a Type-1 histamine reaction. This session is designed to give clarity to the signs of these reactions as well as prevention and treatment strategies. Phase-2 is dominated by Glutathione and Glycine but also these “back-up” hydroxyl reduction in Phase-1. How do pharmaceuticals affect these supports, how clinically can we assess and support them and what does it look like clinically when they are overwhelmed? Additional case studies are discussed. Pharmaceuticals discussed in case presentations will include Mucomyst, Succimer, acetaminophen, codeine, ciclosporin and diazepam.

Multiple sclerosis (MS) is the most common autoimmune disorder affecting the central nervous system. MS affects approximately 400,000 people in the United States, symptoms can start anywhere from 10-80 years of age. No single test can diagnose MS and currently there is no cure. This presentation reviews MS diagnosis, FDA approved disease modifying therapies, and evidence-based natural therapies.

Research suggests that “classic” fibromyalgia (FMS) is a central pain processing disorder and does not appear to be a peripheral somatic disorder. Dr. Brady emphasizes the concept that this central-mediated disorder is strongly associated with psychological disorders, including trauma and abuse history, depression, anxiety, irritable bowel syndrome, and sleep disorder. Common mechanisms in-play regarding these concomitant issues and global pain will be fully explored and accurate differential diagnostic and comprehensive naturopathic therapeutic strategies will be discussed in-detail. The concept of “pseudo” or “false” fibromyalgia diagnostic labels are also discussed, to include various organic and functional medical conditions, as well as somatic musculoskeletal conditions, which confound the accurate diagnosis of “classic” FMS will are also presented.

PTSD is a complex and often debilitating condition. My presentation includes overview of diagnosis, standard of care (including pharmaceutical treatment) for both children and adults, and evidence for integrative therapies including supplements, exercise, yoga, meditation, and writing and theater. There is also discussion about the most evidence based types of psychotherapy. The goal is that at the end of the presentation every person could create an individualized treatment plan for patients who have PTSD, as well as patients who do not meet criteria and are presenting with mood complaints.The pharmaceuticals I discuss include SSRI’s (Prozac, Zoloft, Lexapro, Celexa, Paxil), SNRI’s (Effexor, Cymbalta), Wellbutrin, mood stabilizers (Lamictal, Abilify, Risperidone), alpha agonists (clonidine, guanfacine, prazosin), and benzodiazepine’s (advise against their use). This presentation could be approved for pharmaceutical credits and this section could be lengthened or shortened.

What are the basics of “cause” in the areas of agitation and sleep problems. What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous GABA, Glycine and other calming neurotransmitters benefit and refine your therapies?  What are the basics of “cause” in the areas of depression? What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous serotonin, dopamine and norepinephrine neurotransmitters benefit and refine your therapies?  How does the brain become inflamed and how does that affect neuropsychiatric status? What genomic and nutrigenomic factors can alter this status and restore the brain to a non-inflamed state?  Dr. Anderson discusses case studies that he has worked through in neuro-psychiatric conditions and how they played out. The goal of these cases is to illustrate how genomic assessment and nutrigenomics cross over pharmacology and how they can be implemented clinically.